Vliv léčby inzulinem Fiasp na glykemie, HbA_1c a tělesnou hmotnost u osob s diabetem 1. a 2. typu: studie z reálné praxe

Czech version

Authors: Rudolf Chlup ^1,2,3; Jana Zapletalová ⁴; Hana Zálešáková ³; Johana Kochtová ¹; Richard Kaňa ³
Authors‘ workplace: Ústav fyziologie LF UP v Olomouci ¹; II. interní klinika LF UP a FN Olomouc ²; Odborný léčebný ústav Paseka, p. o., pracoviště Moravský Beroun ³; Ústav lékařské biofyziky LF UP v Olomouci ⁴
Published in: Diab Obez 2019; 19(38): 90-97
Category:

Overview

Aim of this prospective monocentric uncontrolled study was to compare the efficacy of faster‑acting insulin aspart FIASP (insulin aspart + nicotinamid) with the efficacy of previous therapy with insulin aspart.

Method: Three groups of men (N = 36) and women (N = 21) with diabetes were studied: (1) 13 persons with type 1 diabetes (T1DM) treated using continuous subcutaneous insulin infusion (CSII), (2) 17 persons with type 2 diabetes (T2DM) treated by means of CSII and (3) 23 persons with T2DM treated by multiple doses of insulin (MDI) using insulin pens. Treatment efficacy was assessed according to the evolution of plasma glucose concentration (PG) in the course of 10-point glucose profile, mean glucose concentration of this profile (MPG), body mass, HbA_1c, daily insulin dose (INS/d) and patient´s general condition at the beginning and after 2-month treatment period with Fiasp. Fiasp was used according to the identical algorithms as insulin aspart. The Wilcoxon paired rank test was applied to compare the respective parameters obtained with insulin aspart versus Fiasp. P < 0,05 was considered significant.

Results: No adverse events appeared in any group. In T2DM, a tendency to reduction of PG, MPG, HbA_1c, body mass and INS/d in the course of Fiasp therapy was shown, nevertheless, the diffefences have never reached any statistical significance (N < 24).

Conclusion: The evidence of noninferiority of Fiasp versus insulin aspart was demonstrated. Next, the introduction of improved algoritms followed be implemented into Fiasp therapeutic regimen.

Keywords:

faster insulin aspart – insulin aspart – insulin pen – insulin pump – treatment algorithm

Sources

Haahr H, Hövelmann U, Brøndsted L et al. Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart in patients with type 1 diabetes mellitus. Diabetologia 2014; 57(Suppl 1): S1–S564. Dostupné z DOI: <http://doi 10.1007/s00125–014–3355–0>.
Heise T, Haahr H, Jensen L et al. Faster-acting insulin aspart improves postprandial glycaemia versus insulin aspart in patients with type 1 diabetes mellitus. Diabetologia 2014; 57(Suppl 1): S1–S564. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–014–3355–0>.
Sorli C. New developments in insulin therapy for type 2 diabetes. Am J Med 2014; 127(10 Suppl): S39–S48. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2014.07.006>.
Basu A, Pieber TR, Hansen AK et al. Evaluation of early postprandial suppression of endogenous glucose production with faster aspart vs. insulin aspart (77. Scientific Sessions of the American Diabetes Association, June 9 – 13, 2017, San Diego, California). Diabetes 2017; 66(Suppl 1): 960-P (Abstract).
Philis-Tsimikas A, Bode B, Franek F et al. Improved glycemic control with carbohydrate counting for adjustment of fast-acting insulin aspart vs. insulin aspart in subjects with type 1 diabetes (77. Scientific Sessions of the American Diabetes Association, June 9 – 13, 2017, San Diego, California). Diabetes 2017; 66(Suppl 1): 997-P (Abstract).
Rodbard HW, Bowering K, Piletic M et al. Postprandial plasma glucose in target range with faster aspart basal-bolus therapy (77. Scientific Sessions of the American Diabetes Association, June 9 – 13, 2017, San Diego, California). Diabetes 2017;66(Suppl 1): 984-P (Abstract).
Bowering K, Bode BW, Harris SB, et al. The impact of baseline BMI and HbA1c on glycemic control after treatment with fast-acting insulin aspart in individuals with type 2 diabetes (77. Scientific Sessions of the American Diabetes Association, June 9 – 13, 2017, San Diego, California). Diabetes 2017; 66(Suppl 1): 977-P (Abstract).
Mathieu C, Bode BW, Franek E, et al. Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: comparison with insulin aspart in onset 1 (77. Scientific Sessions of the American Diabetes Association, June 9 – 13, 2017, San Diego, California). Diabetes 2017; 66(Suppl 1): 992-P2017 (Abstract).
Heise T, Hövelmann U, Brøndsted L et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 2015; 17(7): 682–688. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12468>.
Fath M, Danne T, Biester T et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatric Diabetes 2017;18(3): 903–910. Dostupné z DOI: <http://dx.doi.org/10.1111/pedi.12506>.
Russell-Jones D, Bode B, de Block C et al. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (Onset 1) Diabetes Care 2017; 40(7): 943–950. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–1771>.
Shiramoto M, Nishida T, Hansen AK et al. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart. J Diabetes Investig 2018; 9(2): 303–310. Dostupné z DOI: <http://dx.doi.org/10.1111/jdi.12697>.
Bowering K, Case C, Harvey J et al. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the Onset 2 trial. Diabetes Care 2017; 40(7): 951–957. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–1770>.
Rodbard H, Tripathy D, Vidrio Velazquez M et al. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomised, 18-week, open-label, phase 3 trial (Onset 3). Diabetes Obes Metab; 19(10): 1389–1396. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12955>.
Mathieu C, Bode BW, Franek E et al. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (Onset 1): A 52-week, randomized, treat-to-target, phase 3 trial. Diabetes Obes Metab 2018; 20(5): 1148–1155. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13205>.
Pieber TR, Svehlikova E, Brunner M et al. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. Diabetes Obes Metab 2019; 21(9):2068–2075. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13767>.
Klonoff DC, Evans ML, Lane W et al. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (Onset 5). Diabetes Obes Metab 2019; 21(4) 961–967. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13610>.
Bode B, Iotova V, Kovarenko M et al. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes: the Onset 7 trial. Diabetes Care 2019; 42(7): 1255–1262. Dostupné z DOI: <http://dx.doi.org/10.2337/dc19–0009>.
Informace dostupné z WWW: https://www.iqvia.com
Chlup R. Využití inzulínových analog v léčbě diabetiků 1. i 2. typu, u těhotných žen i u dětí. Farmakoterapeutická revue 2017; 2017(6): 406–411.
Chlup R, Zálešáková H, Kochtová J et al. Přínos léčby inzulinem Fiasp pro osoby s diabetem 1. a 2. typu. DMEV 2018; 21(Suppl 1): 41 (Abstract).
Olšovský J. Klinické zkušenosti s inzulínem faster aspart – Fiasp. Kazuistiky v diabetologii 2018; 16(2): 25–26.
Urbancová K. Fiasp – první zkušenosti. Kazuistiky v diabetologii 2018; 16(2): 29–31.
Maule P. Fiasp – nová možnost ovlivnění postprandiální glykemie. Kazuistiky v diabetologii 2018; 16(3): 30–32.
Štechová K. Inzulín Fiasp (faster aspart) – příběh první. Kazuistiky v diabetologii 2018; 16(4): 29–31.
Štechová K. Inzulín Fiasp (faster aspart) – příběh druhý. Kazuistiky v diabetologii 2019; 17(1): 25–27.
Štechová K. Inzulín Fiasp (faster aspart) – příběh třetí. Kazuistiky v diabetologii 2019;17(2): 41–44.
Chlup R, Doubravova B, Bartek J et al. Effective Assessment of Diabetes Control Using Personal Glucometers (CONTOURLINK, Bayer, Germany; CALLA, Wellion, Austria; LINUS, Agamatrix, USA). Dis Markers 2013; 35(6): 895–905. Dostupné z DOI: <http:// doi: 10.1155/2013/702427>.
Chlup R, Zapletalová J, Zálešáková H et al. Vliv dvouměsíční léčby ultrarychlým inzulinem aspart (Fiasp) na glykemie, HbA1c a tělesnou hmotnost u osob s diabetem – prospektivní monocentrická studia z reálné praxe. Slovenská diabetologická spoločnosť. Zborník abstraktov (Suppl). 15. Vedecká konferencia, 29. marca 2019 na Zámku v Topolčiankach: 24–30 (Abstract).